Drug Trial Radar · NCT02622113
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Dec 2014
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus. The extension study was an extension to double-blind study of 16 weeks (TA-7284-11)
Conditions
- Type 2 Diabetes Mellitus
Interventions
Canagliflozin (TA-7284)Drug
The patients will receive Canagliflozin orally for 36 weeks
InsulinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events)Time frame: Placebo/CANA: 36 Weeks, CANA/CANA: 52 Weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Reserch site
Chūbu, Japan
Reserch site
Chugoku, Japan
Reserch site
Hokkaido, Japan
Reserch site
Kanto, Japan
Reserch site
Kinki, Japan
Reserch site
Kyushu, Japan
Reserch site
Tōhoku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.